Please use this identifier to cite or link to this item: https://doi.org/10.1155/2014/617102
Title: Consumptive coagulopathy in angiosarcoma: A recurrent phenomenon?
Authors: Farid, M 
Ahn, L
Brohl, A
Cioffi, A
Maki, R.G
Keywords: bevacizumab
carboplatin
cisplatin
doxorubicin
fibrinogen
fibrinogen degradation product
gemcitabine
ifosfamide
navelbine
paclitaxel
pazopanib
rapamycin
ablation therapy
adolescent
adult
aged
angiosarcoma
article
bone marrow metastasis
bone metastasis
brain metastasis
breast cancer
cancer combination chemotherapy
cancer control
cancer localization
cancer prognosis
cancer radiotherapy
cancer size
cancer surgery
cancer survival
carcinomatous meningitis
clinical article
controlled study
disease association
disease duration
disease free survival
disseminated intravascular clotting
epithelioid hemangioendothelioma
female
fibrinogen blood level
heart cancer
hemangioendothelioma
human
liver cancer
liver transplantation
local therapy
lung metastasis
lymph node metastasis
male
mediastinum tumor
medical record review
middle aged
partial mastectomy
pleura metastasis
priority journal
prothrombin time
radiation induced neoplasm
recurrent disease
retrospective study
skull cancer
spine metastasis
spleen metastasis
systemic therapy
thrombocyte count
tumor volume
very elderly
young adult
Issue Date: 2014
Publisher: Hindawi Publishing Corporation
Citation: Farid, M, Ahn, L, Brohl, A, Cioffi, A, Maki, R.G (2014). Consumptive coagulopathy in angiosarcoma: A recurrent phenomenon?. Sarcoma 2014 : 617102. ScholarBank@NUS Repository. https://doi.org/10.1155/2014/617102
Rights: Attribution 4.0 International
Abstract: Objectives. To report the prevalence of consumptive coagulopathy in angiosarcoma patients seen at a single center. Methods. We retrospectively reviewed case records of 42 patients diagnosed with angiosarcoma at Mount Sinai Hospital between 2000 and 2013. Results. Seven patients (17%) met clinical criteria for disseminated intravascular coagulation (DIC) in absence of concomitant clinical states known to cause coagulopathy or myelosuppression. In all patients who received systemic antineoplastic therapy with resultant disease response or stability, DIC resolved in tandem with clinical improvement. DIC recurred at time of disease progression in all cases. Two patients had bulky disease, defined as diameter of largest single or contiguous tumor mass measuring 5 cm or more. All patients demonstrated an aggressive clinical course with short duration of disease control and demise within 1 year. In contrast, evaluation over the same period of 17 epithelioid hemangioendothelioma patients serving as a clinical control group revealed no evidence of DIC. Conclusion. Angiosarcomas can be associated with a consumptive coagulopathy arising in tandem with disease activity. Vigilance for this complication will be needed in the course of often aggressive multimodality therapy. The potential utility of coagulopathy as a prognostic biomarker will need to be explored in future studies. © 2014 Mohamad Farid et al.
Source Title: Sarcoma
URI: https://scholarbank.nus.edu.sg/handle/10635/180766
ISSN: 1357-714X
DOI: 10.1155/2014/617102
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1155_2014_617102.pdf1.3 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

8
checked on May 10, 2022

Page view(s)

124
checked on May 12, 2022

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons